This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-2164v1 69/4/1685    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, X. Articles by McCauley, L. K. Search for Related Content PubMed PubMed Citation Articles by Li, X. Articles by McCauley, L. K.

A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone

¹ Department of Periodontics and Oral Medicine, School of Dentistry, ² Department of Internal Medicine, and ³ Department of Pathology, Medical School, University of Michigan; ⁴ Department of Urology, University of Michigan Urology Center, Ann Arbor, Michigan and ⁵ Ortho Biotech Oncology Research and Development, Centocor R&D, Radnor, Pennsylvania

Requests for reprints: Laurie K. McCauley, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Room 3343, 1011 North University Avenue, Ann Arbor, MI 48109-1078. Phone: 734-647-3206; Fax: 734-763-5503; E-mail: mccauley{at}umich.edu.

Key Words: CCL2 • prostate cancer • parathyroid hormone-related protein

Monocyte chemoattractant protein 1 (CCL2) is a recently identified prominent regulator of prostate cancer growth and metastasis. The purpose of this study was to investigate the mechanistic role of CCL2 in prostate cancer growth in bone. The present study found that CCL2 was up-regulated in osteoblasts (3-fold by PC-3 and 2-fold by VCaP conditioned medium) and endothelial cells (2-fold by PC-3 and VCaP conditioned medium). Parathyroid hormone-related protein (PTHrP) treatment of osteoblastic cells up-regulated CCL2 and was blocked by a PTHrP antagonist, suggesting that prostate cancer–derived PTHrP plays an important role in elevation of osteoblast-derived CCL2. CCL2 indirectly increased blood vessel formation in endothelial cells through vascular endothelial growth factor-A, which was up-regulated 2-fold with administration of CCL2 in prostate cancer cells. In vivo, anti-CCL2 treatment suppressed tumor growth in bone. The decreased tumor burden was associated with decreased bone resorption (serum TRAP5b levels were decreased by 50–60% in anti–CCL2-treated animals from VCaP or PC-3 cell osseous lesions) and microvessel density was decreased by 70% in anti–CCL2-treated animals with bone lesions from VCaP cells. These data suggest that a destructive cascade is driven by tumor cell–derived, PTHrP-mediated induction of CCL2, which facilitates tumor growth via enhanced osteoclastic and endothelial cell activity in bone marrow. Taken together, CCL2 mediates the interaction between tumor-derived factors and host-derived chemokines acting in cooperation to promote skeletal metastasis. [Cancer Res 2009;69(4):1685–92]

This article has been cited by other articles:

				X. Lu and Y. Kang Chemokine (C-C Motif) Ligand 2 Engages CCR2+ Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone J. Biol. Chem., October 16, 2009; 284(42): 29087 - 29096. [Abstract] [Full Text] [PDF]